.jpg?width=780&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto)
TOKYO -- Daiichi Sankyo, a Japanese drugmaker that has not had a blockbuster product for nearly a decade, is surging in market value, joining the 5 trillion yen ($46 billion) club that also includes such marquee names as Nintendo and Honda Motor.
The drugmaker pulled off a major breakthrough in cancer treatment using traditional research methods largely abandoned by bigger rivals. The new drug, Enhertu, was approved by the U.S. Food and Drug Administration late last year and launched this month, spurring a market rally.
